The genetic testing firm 23andMe has filed for bankruptcy, another twist in the story of a company that promised a pioneering approach to precision health. Now users are scrambling to delete their personal data, with the future ownership of the firm uncertain. To understand the highs and lows of 23andMe’s journey, Madeleine Finlay hears from the Guardian US ... Show More
Sep 13
Live episode: how AI is reshaping our minds
In this episode of Science Weekly, recorded in front of an audience at the London podcast festival on 3 September, Ian Sample hears from Michael Safi, the host of the Guardian’s chart-topping podcast about artificial intelligence, Black Box. In series two, Black Box: the chatbots ... Show More
1h 22m
Apr 2025
DNA and Bankruptcy Collide With 23andMe
The genetic testing company 23andMe filed for bankruptcy in March, after years of slowing sales, legal trouble, and a declining stock price. And now, the valuable trove of genetic data the company owns is for sale, sparking privacy concerns. On today’s Big Take, Bloomberg biotec ... Show More
16m 30s
Jun 2025
23andMe's Fatal Flaw | Guess Who’s Back | 3
Just when it looked like 23andMe was selling to Regeneron Pharmaceuticals, founder Anne Wojcicki placed a bid through her new nonprofit in an attempt to win it back at the eleventh hour. Lila MacLellan, Senior Writer at Fortune, joins David to discuss Wojcicki’s leadership style, ... Show More
37m 55s
Aug 2024
How 23andMe went from a $6 billion valuation to trading for pennies
Cofounder and CEO of 23andMe, Anne Wojcicki, wants to take the public company private. Founded in 2006, the DNA-testing startup was valued at $6 billion in 2021. Now, it’s trading for less than a dollar. So what happened? ‘Fast Company’ senior writer Ainsley Harris breaks down 23 ... Show More
54m 45s